RTX vs SPRY · P/E 36, rev $88.60B vs rev $89.1M
RTX Corporation (RTX) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the RTX and SPRY stock pages for the full models.
Not investment advice.